PSMA (prostate-specific membrane antigen), also known as FOLH1 (folate hydrolase 1), NAALAD1 (N-acetylated-α-linked acidic dipeptidase I), GCPII (glutamate  carboxypeptidase II), FGCP (folypoly¬γ¬glutamate carboxypeptidase ), and GIG27 (cell growth-inhibiting gene 27 protein), is a tumor marker in prostate cancer.  PSMA is a single pass type II transmembrane zinc metallopeptidase that belongs to the peptidase M28 family and M28B subfamily. PSMA is most highly expressed in the nervous system, prostate, kidney, and small intestine. PSMA has folate hydrolase and N-acetylated-α-linked-acidic dipeptidase (NAALADase) activity with a preference for tri-alpha-glutamate peptides. In the intestine, PSMA hydrolyzes folylpoly¬γ-glutamates, facilitating the uptake of folate. Genetic variation in PSMA may be associated with low folate levels and consequent hyperhomocysteinemia. In the brain, PSMA modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate, another neurotransmitter. Inhibition of brain PSMA activity is considered to be a promising approach for the treatment of neurological disorders associated with glutamate excitotoxicity, such as stroke, chronic pain, and amyotrophic lateral sclerosis. PSMA also exhibits a dipeptidyl-peptidase IV (DPPIV) type activity. PSMA is involved in tumor progression In the prostate and used as an effective diagnostic and prognostic indicator of prostate cancer.

PSMA (prostate-specific membrane antigen), also known as FOLH1 (folate hydrolase 1), NAALAD1 (N-acetylated-α-linked acidic dipeptidase I), GCPII (glutamate  carboxypeptidase II), FGCP (folypoly¬γ¬glutamate carboxypeptidase ), and GIG27 (cell growth-inhibiting gene 27 protein), is a tumor marker in prostate cancer.  PSMA is a single pass type II transmembrane zinc metallopeptidase that belongs to the peptidase M28 family and M28B subfamily. PSMA is most highly expressed in the nervous system, prostate, kidney, and small intestine. PSMA has folate hydrolase and N-acetylated-α-linked-acidic dipeptidase (NAALADase) activity with a preference for tri-alpha-glutamate peptides. In the intestine, PSMA hydrolyzes folylpoly¬γ-glutamates, facilitating the uptake of folate. Genetic variation in PSMA may be associated with low folate levels and consequent hyperhomocysteinemia. In the brain, PSMA modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate, another neurotransmitter. Inhibition of brain PSMA activity is considered to be a promising approach for the treatment of neurological disorders associated with glutamate excitotoxicity, such as stroke, chronic pain, and amyotrophic lateral sclerosis. PSMA also exhibits a dipeptidyl-peptidase IV (DPPIV) type activity. PSMA is involved in tumor progression In the prostate and used as an effective diagnostic and prognostic indicator of prostate cancer.

 

Product Details

 

Gene Symbol: PSMA; FOLH1; PSM; FGCP; FOLH; GCP2; mGCP; GCPII; NAALAD1; NAALAdase

 

NCBI Gene ID: 2346

 

Uniprot Entry: Q04609

  

Construct Details: Expressed as the combination of a heavy chain (HC) containing VH from anti-human PSMA mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-human PSMA mAb and CL of human kappa light chain.  Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition (see the gel image above, labeled as DTT "-").

 

Source:  Mamamlian cells stably expressing anti-human PSMA human heavy chain and light chain and growing in chemical-defined media with no animal components or antibiotics 

 

M.W.: Calculated molecular mass (kDa): 146 (49 kDa for a single HC, 24 kDa for a single LC); Estimated by SDS-PAGE under reducing condition(kDa): 50 kDa + 25 kDa.

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as DTT "+")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier free). 

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to human PSMA with high affinity and recognizes cell surface PSMA by flow cytometry, IHC staining and fluorescent microscopy. 

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Cancer Res. 53:227-230(1993)

2. Pro. Natl. Acad. Sci. 93:749 (1996)

3. Clin. Cancer Res. 3:81 (1997) 

4. J. Biol. Chem. 274:8470-8483(1999)

5. Prostate 67:1791-1800(2007)

 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: MAB2617-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.